Atlantic Peptides, a custom peptide synthesizer based out of Lewisburg, announces that it will now offer the 29-chain amino acid, Glucagon, to scientific research laboratories and academia institutions for research pertaining to the treatment and therapy of diabetes.

Atlantic Peptides (http://www.atlanticpeptides.com/), a custom peptide manufacturer that works with scientific research laboratories and academic institutions from around the world, announces that it will now offer Glucagon as one of its amino acid peptides. The hormones contained in the 29-chain amino acid counter the regulatory functions of insulin, and have been aggressively researched throughout the decade as a potential treatment of diabetes.

Glucagon is manufactured in the pancreas of both animals and humans, and has the ability to increase low levels of blood sugar, thereby increasing one’s blood glucose concentration for the treatment of hypoglycemia – a life threatening condition that may render a victim unconscious if lacking the appropriate amounts of glucose in the bloodstream. In addition, the peptide hormone triggers the liver to convert stored glycogen into glucose, which may then act even further to signal the body to release insulin.

Although it may be effective in this nature, it also may play a danger in producing toxic fibrils, which is why the peptide has been researched quite extensively throughout the years.

“More than 25 million Americans have diabetes,” said Jon Hanson, “which is why Atlantic Peptides is now offering the peptide to our researchers. We’ve had an influx of requests for the peptide, because the medical industries are looking to find a solution, or at least a form of therapy, to help alleviate the health consequences of this life threatening disease.”

Atlantic Peptides offers an array of custom and catalog peptides to the research industries, and also manufacturers polyclonal and monoclonal antibodies. It also works closely with the pharmaceutical industry, by supplying peptides for those conducting pre-GMP studies through cGMP manufacture.

The Lewisburg facility also offers competitive prices with online quotes, and its analytical instruments are checked and calibrated weekly to ensure the accurate production of antibodies and development of assay(s).

For more information about Atlantic Peptides, visit www.atlanticpeptides.com.

About Atlantic Peptides

Atlantic Peptides manufactures synthetic peptides, as well as provides mono- and poly-clonal antibodies to the academic and life-science industries across the world. Atlantic Peptides also offers personalized, custom services to address individual business needs, and also works with pharmaceutical industries for research studies.

Atlantic Peptides, a Pennsylvania-based peptide manufacturer and distributor to academia entities and pharmaceutical companies, announces the launch of its latest product, the H-9019 (echistatin) peptide.

Atlantic Peptides (http://www.atlanticpeptides.com/), a leading peptide manufacturer to academia entities and pharmaceutical companies, announces the launch of its latest product, the H-9019 (or echistatin) peptide. The product addition marks the ongoing expansion within the company to better serve clientele focused on peptide therapeutics.

The H-9019 peptide, also known as echistatin by scientific terminology, is a 49-amino acid polypeptide, or chain, with 4 cystine bridges from the venom of a snake, the saw-scaled viper (known as Echis carinatus). The polypeptide contains an RGD sequence that binds to glycoprotein receptors on platelets and inhibits ADP-stimulated platelet aggregation with IC50 = 3.3 x 10(-8) M. In addition, the peptide stimulates osteolastic bone resportion, both in vitro and in vivo; and, the reduction of purified synthetic echistatin to octahydroechistatin with dithiothreitol, combined with air oxidation, regenerated a quantitative yield of identical echistatin sequences.

“We’ve worked with institutions for more than 15 years, and boast a staff with more than 40 years of experience,” said Jon Hanson. “By expanding our product line, we’re able to work with even more clients, who can see why our current base attests to the quality and quick turnaround of our products and services.”

The Pennsylvania-based company, Atlantic Peptides, manufactures and distributes just that – customized synthetic peptides for pre-GMP research studies for the production of antibodies, as well as provides labeled peptides for assay development. In addition, Atlantic Peptides also supplies polyclonal and monoclonal antibodies to national and international entities for laboratory use.

In addition to offering echistatin to the market, Atlantic Peptides offers the following peptides (link: http://www.atlanticpeptides.com/products-page/), which can be ordered offline: amyloid peptides, antimicrobial and related peptides, cancer research peptides, cell permeable peptides and drug delivery peptides, GPCR peptides, Ghrelin peptides, MOG peptides, OVA peptides, and proteolipid proteins.

Along with the use of skilled experts and cutting-edge technology, the peptide manufacturer can deliver research peptides ranging from the milligram to the kilogram in weight, and can compose peptides of more than 130 amino acids in length.

For more information, or to order online, visit http://www.atlanticpeptides.com.

About Atlantic Peptides

Atlantic Peptides manufactures synthetic peptides, as well as provides mono- and poly-clonal antibodies to the academic and life-science industries across the world. Atlantic Peptides also offers personalized, custom services to address individual business needs, and also works with pharmaceutical industries for research studies.